RecruitingNot ApplicableNCT07333053

Clinical Efficacy of Transarterial Infusion Chemotherapy for Unresectable Colorectal Cancer

FOLFOX-Based Transarterial Infusion Chemotherapy for Unresectable Colorectal Cancer: An Open-Label, Multicenter, Randomized, Controlled, Phase Ⅱ Trial


Sponsor

Quanda Liu

Enrollment

30 participants

Start Date

Mar 31, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This is a prospective, multicenter, randomized, and open-label clinical trial. It is initiated to determine the efficacy of FOLFOX-based, transarterial infusion chemotherapy (TAIC) combined with either cetuximab or bevacizumab for patients with unresectable colorectal cancer (CRC).


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is evaluating the effectiveness of delivering chemotherapy directly into the arteries supplying a colorectal tumor (transarterial infusion chemotherapy) for patients whose cancer cannot be removed by surgery. **You may be eligible if...** - You are 18 or older - You have been diagnosed with colorectal cancer confirmed by CT/MRI and biopsy - Surgery is not an option due to your health or the size/location of the tumor - You have not previously received chemotherapy, or your cancer still responds to chemotherapy - Your blood counts and organ function (liver, kidneys, heart) meet the required thresholds **You may NOT be eligible if...** - You have another primary cancer elsewhere in the body - You have a hole (perforation) in your gut - You are allergic to the chemotherapy drugs being used - You are pregnant, breastfeeding, or planning pregnancy - You are receiving other cancer treatments at the same time Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURETransarterial infusion chemotherapy (TAIC)

TAIC can increase the local intra-tumoral concentrations of chemotherapeutic agents by intensifying drug delivery into the tumor via super-selective catheterization of the tumor-feeding artery, and meanwhile reduce systematic toxicity.

PROCEDUREIntravenous Chemotherapy(IVC)

Intravenous administration of chemotherapeutic agents is the mainstay of chemotherapy.


Locations(1)

Guang'anmen Hospital, China Academy of Chinese Medical Sciences

Xicheng, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07333053